未经证实:毛细血管扩张型骨肉瘤(TOS)是一种罕见但高度恶性的骨肉瘤亚型。虽然手术治疗是骨肉瘤的主要治疗方式,缺乏关于不同手术方法对TOS患者的益处的证据.本研究旨在比较不同手术和辅助治疗对TOS患者总生存期的影响。以及患者人口统计的关联,肿瘤特征,和社会经济地位对治疗结果的影响。
UNASSIGNED:这项回顾性研究选择了监测中登记的四肢最常见的TOS病例,流行病学,和1989年至2019年的最终结果(SEER)数据库。单因素和多因素Cox回归模型用于分析所有预后因素。和Kaplan-Meier分析了疾病特异性治疗生存因素.
UNASSIGNED:共127例患者纳入分析。初次诊断时的平均年龄为20.09岁。在单变量分析中,最初诊断时没有转移,保肢手术,辅助化疗,没有区域淋巴结清扫与较低的死亡风险相关。多因素分析进一步显示是否存在远处转移和区域淋巴结清扫,实施辅助化疗,手术方式的选择是预后的独立预测因素。
UNASSIGNED:远处转移和区域淋巴结清扫与TOS预后较差相关,截肢手术没有比保肢手术更好的预后。与常规化疗相比,新辅助化疗并未显著改善TOS的预后。
UNASSIGNED: Telangiectatic osteosarcoma (TOS) is a rare but highly malignant subtype of osteosarcoma. Although surgical treatment is the primary treatment modality for osteosarcoma, evidence on the benefits of different surgical methods in patients with TOS is lacking. This study aimed to compare the effects of different surgical and adjuvant treatments on overall survival of TOS, and the association of patient demographics, oncological characteristics, and socioeconomic status on treatment outcomes.
UNASSIGNED: This retrospective study selected the most common TOS cases of the extremities registered in the Surveillance, Epidemiology, and End Results (SEER) database from 1989 to 2019. Univariate and multivariate Cox regression models were used to analyze all prognostic factors, and Kaplan-Meier analyses were performed for disease-specific treatment factors of survival.
UNASSIGNED: A total of 127 patients were included in the analysis. The average age at initial diagnosis was 20.09 years. In univariate analyses, the absence of metastasis at initial diagnosis, limb-salvage surgery, adjuvant chemotherapy, and no regional lymph node dissection were associated with a lower risk of death. Multivariate analysis further showed that the presence or absence of distant metastasis and regional lymph node dissection, implementation of adjuvant chemotherapy, and choice of surgical method were independent predictors of prognosis.
UNASSIGNED: Distant metastasis and regional lymph node dissection are associated with poorer outcomes in TOS, and amputation has no better prognosis than limb salvage surgery. Compared with conventional chemotherapy, neoadjuvant chemotherapy did not significantly improve the prognosis of TOS.